Pharmacological actions of cannabinoids

Handbook of Experimental Pharmacology

Volumn 168, Issue , 2005, Pages 1-51

  Pertwee, R G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Abnormal cannabidiol; Cannabidiol; Cannabinoid receptor agonists and antagonists; Cannabinoid receptors; Inverse agonism

Indexed keywords

EID: 84884474728     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/3-540-26573-2_1     Document Type: Article

References (231)

1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A (1994) (R)-methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889-1893
2. Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, Razdan RK, Martin BR (1995) Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 273:1172-1181
3. Ahluwalia J, Yaqoob M, Urban L, Bevan S, Nagy I (2003) Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. J Neurochem 84:585-591
4. Akinshola BE, Chakrabarti A, Onaivi ES (1999a) In-vitro and in-vivo action of cannabinoids. Neurochem Res 24:1233-1240
5. Akinshola BE, Taylor RE, Ogunseitan AB, Onaivi ES (1999b) Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP. Naunyn Schmiedebergs Arch Pharmacol 360:242-248
6. Al-Hayani A, Wease KN, Ross RA, Pertwee RG, Davies SN (2001) The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacology 41:1000-1005
7. Balster RL, PrescottWR (1992) Δ9-Tetra Hydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 16:55-62
8. Barann M, Molderings G, Brüss M, Bönisch H, Urban BW, Göthert M(2002)Direct inhibition by cannabinoids of human 5-HT3A receptors: Probable involvement of an allosteric modulatory site. Br J Pharmacol 137:589-596
9. Bayewitch M, Rhee M-H, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z (1996) (-)-Δ9-Tetra Hydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271:9902-9905
10. Begg M, Mo F-M, Offertáler L, Bátkai S, Pacher P, Razdan RK, Lovinger DM, Kunos G (2003) G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. J Biol Chem 278:46188-46194
11. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee M-H, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R (1998) An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-Arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353:23-31
12. Berdyshev EV, Schmid PC, Krebsbach RJ, Hillard CJ, Huang CS, Chen N, Dong Z, Schmid HHO(2001)Cannabinoid-receptor-independent cell signallingby N-Acylethanolamines. Biochem J 360:67-75
13. Bisogno T, Melck D, Bobrov MY, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V (2000) N-Acyl-dopamines: Novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351:817-824
14. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845-852
15. Breivogel CS, Childers SR (2000) Cannabinoid agonist signal transduction in rat brain: Comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther 295:328-336
16. Breivogel CS, Sim LJ, Childers SR (1997) Regional differences in cannabinoid receptor/Gprotein coupling in rat brain. J Pharmacol Exp Ther 282:1632-1642
17. Breivogel CS, Selley DE, Childers SR (1998) Cannabinoid receptor agonist efficacy for stimulating [35S]GTPγS binding to rat cerebellarmembranes correlateswith agonist-induced decreases in GDP affinity. J Biol Chem 273:16865-16873
18. Breivogel CS, Griffin G, DiMarzo V, Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163
19. Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJR, Brown P, Bridges D, Ledent C, Bifulco M, Rice ASC, Di Marzo V, Baker D (2002) Arvanil-induced inhibition of spasticity and persistent pain: Evidence for therapeutic sites of action different fromthe vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. Eur J Pharmacol 439:83-92
20. Busch-Petersen J, Hill WA, Fan PS, Khanolkar A, Xie X-Q, Tius MA, Makriyannis A (1996)Unsaturated side chain β-11-hydroxyhexahydrocannabinol analogs. JMed Chem 39:3790-3796
21. Calandra B, Portier M, Kernéis A, Delpech M, Carillon C, Le Fur G, Ferrara P, Shire D (1999) Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur J Pharmacol 374:445-455
22. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. Nature 394:277-281
23. Calignano A, La Rana G, Piomelli D (2001) Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419:191-198
24. Chaytor AT, Martin PEM, Evans WH, Randall MD, Griffith TM (1999) The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 520:539-550
25. Cheer JF, Cadogan A-K, Marsden CA, Fone KCF, Kendall DA (1999) Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38:533-541
26. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P (2001) Direct inhibition of T-Type calcium channels by the endogenous cannabinoid anandamide. EMBO J 20:7033-7040
27. Chin C, Lucas-Lenard J, Abadji V, Kendall DA. (1998)Ligand binding andmodulationof cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem 70:366-373
28. Christopoulos A, Wilson K (2001) Interaction of anandamide with the M1 and M4 muscarinic acetylcholine receptors. Brain Res 915:70-78
29. Compton DR, Aceto MD, Lowe J, Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): Inhibition of Δ9-Tetra Hydrocannabinolinduced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594
30. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G (2002) Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 135:181-187
31. Cosenza M, Gifford AN, Gatley SJ, Pyatt B, Liu Q, Makriyannis A, Volkow ND(2000) Locomotor activityandoccupancyof braincannabinoidCB1 receptorsby theantagonist/inverse agonist AM281. Synapse 38:477-482
32. Costa B, Colleoni M(1999) SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists. Acta Pharmacol Sin 20:1103-1108
33. Craib SJ, Ellington HC, Pertwee RG, Ross RA (2001) A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol 134:30-37
34. Cravatt BF, Lichtman AH (2002) The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids 121:135-148
35. Darlington CL (2003) Dexanabinol: A novel cannabinoid with neuroprotective properties. IDrugs 6:976-979
36. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agrò A, Di Marzo V (2001a) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 276:12856-12863
37. DePetrocellis L, Davis JB, DiMarzo V(2001b)Palmitoylethanolamide enhancesanandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 506:253-256
38. De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V (2002) Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol 16:297-302
39. De Vry J, Jentzsch KR (2002) Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist. Eur J Pharmacol 457:147-152
40. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
41. Devlin MG, Christopoulos A (2002)Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. J Neurochem 80:1095-1102
42. Di Marzo V, Melck D, Bisogno T, De Petrocellis L (1998) Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21:521-528
43. Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, Zimmer A, Martin BR (2000) Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: Evidence for non-CB1, non-CB2 receptormediated actions of anandamide in mouse brain. J Neurochem 75:2434-2444
44. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, Davis JB, Dasse O, Mahadevan A, Razdan RK, Martin BR (2001) Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor hybrid ligands. Biochem Biophys Res Commun 281:444-451
45. DiMarzo V, Griffin G, De Petrocellis L, Brandi I, Bisogno T, Williams W, Grier MC, Kulasegram S, Mahadevan A, Razdan RK, Martin BR (2002) A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J Pharmacol Exp Ther 300:984-991
46. Dinh TP, Freund TF, Piomelli D (2002) A role for monoglyceride lipase in 2-Arachidonoylglycerol inactivation. Chem Phys Lipids 121:149-158
47. Drysdale AJ, Pertwee RG, Platt B (2004)Modulation of calcium homeostasis by cannabidiol in primary hippocampal culture. Proc Br Pharmacol Soc at http://www.pa2online.org/Vol1Issue4abst052P.html
48. El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai N-J, Roon P, Caldwell RB, Caldwell RW, Green K, Liou GI (2003) Neuroprotective effect of (-)Δ9-Tetra Hydrocannabinol and cannabidiol in N-methyl-d-Aspartate- induced retinal neurotoxicity: Involvement of peroxynitrite. Am J Pathol 163:1997-2008
49. Ellington HC, Cotter MA, Cameron NE, Ross RA (2002) The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release fromthe isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology 42:966-975
50. ElSohly MA (2002) Chemical constituents of cannabis. In: Grotenhermen F, Russo E (eds) Cannabis and Cannabinoids Pharmacology, Toxicology and Therapeutic Potential. Haworth Press, New York, pp 27-36
51. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A (2003) Cannabinoids ablate release of TNFa in rat microglial cells stimulated with lipopolysaccharide. Glia 41:161-168
52. Fan P (1995) Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 73:907-910
53. Fan S-F, Yazulla S (2003) Biphasicmodulation of voltage-dependent currents of retinal cones by cannabinoid CBI receptor agonist WIN 55212-2. Visual Neurosci 20:177-188
54. Farquhar-Smith WP, Rice ASC (2001) Administration of endocannabinoids prevents a referredhyperalgesia associatedwithinflammationof the urinary bladder. Anesthesiology 94:507-513
55. Farquhar-Smith WP, Jaggar SI, Rice ASC (2002) Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors. Pain 97:11-21
56. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 90:7656-7660
57. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450
58. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chaney MO, Koppel GA, Brownstein M(1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284:291-297
59. Ferraro L, Tomasini MC, Gessa GL, Bebe BW, Tanganelli S, Antonelli T (2001) The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: An in vivo and in vitro study. Cerebral Cortex 11:728-733
60. Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V(2002)Noladin ether, a putative novel endocannabinoid: Inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett 513:294-298
61. Fowler CJ (2003) Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents: Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of Nacyl ethanolamine breakdown as therapeutic strategies to avoid psychotropic effects. Brain Res Rev 41:26-43
62. Franklin A, Stella N (2003) Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol- sensitive receptors. Eur J Pharmacol 474:195-198
63. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N(2003)Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 23:7767-7775
64. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, Blau H, Mechoulam R (2003) Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: Evidence for a CB3 receptor. Eur J Pharmacol 461:27-34
65. Gallant M, Dufresne C, Gareau Y, Guay D, Leblanc Y, Prasit P, Rochette C, Sawyer N, Slipetz DM, Tremblay N, Metters KM, Labelle M (1996) New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg Med Chem Lett 6:2263-2268
66. Gallily R, Even-Chen T, Katzavian G, Lehmann D, Dagan A, Mechoulam R (2003) γ-Irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 44:1767-1773
67. Gareau Y, Dufresne C, Gallant M, Rochette C, Sawyer N, Slipetz DM, Tremblay N, Weech PK, Metters KM, Labelle M (1996) Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg Med Chem Lett 6:189-194
68. Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, Gifford AN, Pyatt B, Dewey SL, Makriyannis A (1998) Imaging the brain marijuana receptor: Development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem 70:417-423
69. Gérard CM, Mollereau C, Vassart G, Parmentier M (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279:129-134
70. Gifford AN, Tang Y, Gatley SJ, Volkow ND, Lan R, Makriyannis A (1997) Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett 238:84-86
71. Gifford AN, Makriyannis A, Volkow ND, Gatley SJ (2002) In vivo imaging of the brain cannabinoid receptor. Chem Phys Lipids 121:65-72
72. Glass M, Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327-5333
73. Godlewski G, Göthert M, Malinowska B (2003) Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex. Br J Pharmacol 138:767-774
74. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW (2000) Endocannabinoid 2-Arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. Mol Pharmacol 57:1045-1050
75. Göthert M, Brüss M, Bönisch H, Molderings GJ (1999) Presynaptic imidazoline receptors: New developments in characterization and classification. AnnN Y Acad Sci 881:171-184
76. Goutopoulos A, Fan P, Khanolkar AD, Xie X-Q, Lin S, Makriyannis A (2001) Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg Med Chem 9:1673-1684
77. Griffin G, Fernando SR, Ross RA, McKay NG, Ashford MLJ, Shire D, Huffman JW, Yu S, Lainton JAH, Pertwee RG (1997) Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 339:53-61
78. Griffin G, Tao Q, Abood ME (2000) Cloning and pharmacological characterization of the rat CB2 cannabinoid receptor. J Pharmacol Exp Ther 292:886-894
79. Hájos N, Freund TF (2002a) Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43:503-510
80. Hájos N, Freund TF (2002b) Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 121:73-82
81. Hájos N, Katona I, Naiem SS, Mackie K, Ledent C, Mody I, Freund TF (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12:3239-3249
82. Hájos N, Ledent C, Freund TF (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106:1-4
83. Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)Δ9-Tetra Hydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268-8273
84. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J (2000) Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 899:274-282
85. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E (1999) HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96:14228-14233
86. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662-3665
87. Helyes Z, Németh J, Thán M, Bölcskei K, Pintér E, Szolcsányi J (2003) Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci 73:2345-2353
88. Hermann H, De Petrocellis L, Bisogno T, SchianoMoriello A, Lutz B, DiMarzo V(2003) Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci 60:607-616
89. Hillard CJ (2000) Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-Arachidonylglycerol. Prostaglandins Other Lipid Mediat 61:3-18
90. Hillard CJ, Jarrahian A (2003) Cellular accumulation of anandamide: Consensus and controversy. Br J Pharmacol 140:802-808
91. Hillard CJ, Manna S, Greenberg MJ, Dicamelli R, Ross RA, Stevenson LA, Murphy V, Pertwee RG, Campbell WB (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289:1427-1433
92. Hirst RA, Almond SL, Lambert DG (1996) Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. Neurosci Lett 220:101-104
93. Ho W-SV, Hiley CR (2003) Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol 138:1320-1332
94. Howlett AC (1987) Cannabinoid inhibition of adenylate cyclase: Relative activity of constituents and metabolites of marihuana. Neuropharmacology 26:507-512
95. Howlett AC, Fleming RM(1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26:532-538
96. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202
97. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD, Reggio PH(1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39:3875-3877
98. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR (1999) 3-(1',1'-dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: Synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7:2905-2914
99. Huffman JW, Bushell SM, Miller JRA, Wiley JL, Martin BR (2002) 1-methoxy-, 1-deoxy-11-hydroxy-And 11-hydroxy-1-methoxy-Δ8- Tetrahydrocannabinols: New selective ligands for the CB2 receptor. Bioorg Med Chem 10:4119-4129
100. Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song Z-H, Nie J, Lewis D, Reggio PH (2002) N-(Piperidin-1-yl)-5-(4-chlorophenyl) -1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 62:1274-1287
101. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100:10529-10533
102. Iversen L (2003) Cannabis and the brain. Brain 126:1252-1270
103. Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T (2001) In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 296:420-425
104. Izzo AA, Mascolo N, Tonini M, Capasso F (2000) Modulation of peristalsis by cannabinoid CB1 ligands in the isolated guinea-pig ileum. Br J Pharmacol 129:984-990
105. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct fromCB1 or CB2 receptors. Proc Natl Acad Sci USA 96:14136-14141
106. Jarrahian A, Manna S, Edgemond WS, Campbell WB, Hillard CJ (2000) Structure-Activity relationships among N-Arachidonylethanolamine (anandamide) head group analogues for the anandamide transporter. J Neurochem 74:2597-2606
107. Jarrahian A, Watts VJ, Barker EL (2004) D2 dopamine receptors modulate Ga-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 308:880-886
108. Jennings EA, Vaughan CW, Roberts LA, Christie MJ (2003) The actions of anandamide on rat superficial medullary dorsal horn neurons in vitro. J Physiol 548:121-129
109. Jordt S-E, Bautista DM, Chuang H, McKemy DD, Zygmunt PM, Högestätt ED, Meng ID, Julius D (2004) Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427:260-265
110. Kelley BG, Thayer SA (2004) Δ9-Tetra Hydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture. Neuropharmacology 46:709-715
111. Kenny LC, Baker PN, Kendall DA, Randall MD, Dunn WR (2002) The role of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women. Br J Pharmacol 136:1085-1088
112. Khanolkar AD, Abadji V, Lin S, Hill WAG, Taha G, Abouzid K, Meng Z, Fan P, Makriyannis A (1996) Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem 39:4515-4519
113. Köfalvi A, Vizi ES, Ledent C, Sperlágh B (2003) Cannabinoids inhibit the release of [3H]glutmate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. Eur J Neurosci 18:1973-1978
114. Kojima S, Sugiura T, Waku K, Kamikawa Y (2002) Contractile response to a cannabimimetic eicosanoid, 2-Arachidonoylglycerol, of longitudinal smoothmuscle fromthe guinea-pig distal colon in vitro. Eur J Pharmacol 444:203-207
115. Krishnamurthy M, Ferreira AM, Moore BM(2003) Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids. BioorgMed Chem Lett 13:3487-3490
116. Lambert DM, DiPaolo FG, Sonveaux P, Kanyonyo M, Govaerts SJ, Hermans E, Bueb J-L, Delzenne NM, Tschirhart EJ (1999) Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB2 cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta 1440:266-274
117. Lan R, Gatley J, Lu Q, Fan P, Fernando SR, Volkow ND, Pertwee R, Makriyannis A (1999a) Design and synthesis of the CB1 selective cannabinoid antagonist AM281: A potential human SPECT ligand. AAPS PharmSci 1:U13-U24
118. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, Makriyannis A (1999b) Structure-Activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42:769-776
119. Landsman RS, Makriyannis A, Deng H, Consroe P, Roeske WR, Yamamura HI (1998) AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sci 62:PL109-113
120. Ledent C, Valverde O, Cossu G, Petitet F, Aubert J-F, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M(1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404
121. Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, Makriyannis A (1998) Novel analogues of arachidonylethanolamide (anandamide): Affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem 41:5353-5361
122. Maccarrone M, Cartoni A, Parolaro D, Margonelli A, Massi P, Bari M, Battista N, Finazzi-Agrò A (2002) Cannabimimetic activity, binding, and degradation of stearoylethanolamide within the mouse central nervous system. Mol Cell Neurosci 21:126-140
123. Maccarrone M, Bari M, Del PrincipeD, Finazzi-Agrò A (2003) Activation of human platelets by 2-Arachidonoylglycerol is enhanced by serotonin. Thromb Haemost 89:340-347
124. Mackie K, Devane WA, Hille B (1993) Anandamide, an endogenous cannabinoid, inhibits calciumcurrents as a partial agonist in N18 neuroblastoma cells.Mol Pharmacol 44:498-503
125. MacLennan SJ, Reynen PH, Kwan J, Bonhaus DW (1998) Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 124:619-622
126. Maneuf YP, Brotchie JM (1997) Paradoxical action of the cannabinoidWIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120:1397-1398
127. Mang CF, Erbelding D, Kilbinger H (2001) Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br J Pharmacol 134:161-167
128. Marinelli S, Vaughan CW, Christie MJ, Connor M(2002) Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro. J Physiol 543:531-540
129. Marinelli S, Di Marzo V, Berretta N, Matias I, Maccarrone M, Bernardi G, Mercuri NB (2003) Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci 23:3136-3144
130. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1. J Neurochem 80:448-456
131. Martin B, Stevenson LA, Pertwee RG, Breivogel CS, Williams W, Mahadevan A, Razdan RK (2002) Agonists and silent antagonists in a series of cannabinoid sulfonamides. Symposium on the Cannabinoids. Burlington, Vermont, International Cannabinoid Research Society, p 2
132. Martin BR, Thomas BF, Razdan RK(1995) Structural requirements for cannabinoid receptor probes. In: Pertwee RG (ed) Cannabinoid receptors. Academic Press, London, pp 35-85
133. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308:838-845
134. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
135. Mauler F, Mittendorf J, Horváth E, De Vry J (2002) Characterization of the diarylether sulfonylester (-)-(R)-3-(2- hydroxymethylindanyl-4-oxy)phenyl-4,4,4-Trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 302:359-368
136. Mauler F, Hinz V, Augstein K-H, Fassbender M, Horváth E (2003)Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res 989:99-111
137. Mechoulam R, Gaoni Y (1967) Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst 25:175-213
138. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90
139. Mechoulam R, Fride E, Di Marzo V (1998) Endocannabinoids. Eur J Pharmacol 359:1-18
140. Mechoulam R, Panikashvili D, Shohami E(2002) Cannabinoids and brain injury: Therapeutic implications. Trends Mol Med 8:58-61
141. Millns PJ, Chapman V, Kendall DA (2001) Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. Br J Pharmacol 132:969-971
142. Misner DL, Sullivan JM (1999)Mechanism of cannabinoid effects on long-Termpotentiation and depression in hippocampal CA1 neurons. J Neurosci 19:6795-6805
143. Mo FM, Offertáler L, Kunos G (2004) Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct fromCB1, CB2 or EDG-1. Eur J Pharmacol 489:21-27
144. Molderings GJ, Göthert M(1999) Imidazoline binding sites and receptors in cardiovascular tissue. Gen Pharmacol 32:17-22
145. Molderings GJ, Bönisch H, Hammermann R, Göthert M, Br?ss M (2002) Noradrenaline release-inhibiting receptors on PC12 cells devoid of a2-And CB1 receptors: Similarities to presynaptic imidazoline and edg receptors. Neurochem Int 40:157-167
146. Monory K, Tzavara ET, Lexime J, Ledent C, Parmentier M, Borsodi A, Hanoune J (2002) Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun 292:231-235
147. Mussinu J-M, Ruiu S, Mulè AC, Pau A, Carai MAM, Loriga G, Murineddu G, Pinna GA (2003) Tricyclic pyrazoles. Part 1: Synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1 and CB2 cannabinoid receptors. Bioorg Med Chem 11:251-263
148. Németh J, Helyes Z, Thán M, Jakab B, Pintér E, Szolcsányi J (2003) Concentration-dependent dual effect of anandamide on sensory neuropeptide release from isolated rat tracheae. Neurosci Lett 336:89-92
149. New DC, Wong YH (2003) BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: Signalling via cAMP and inositol phosphates. FEBS Lett 536:157-160
150. Offertáler L, Mo F-M, Bátkai S, Liu J, Begg M, Razdan RK, Martin BR, Bukoski RD, Kunos G (2003) Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63:699-705
151. Onaivi ES, Chakrabarti A, Gwebu ET, Chaudhuri G (1996) Neurobehavioral effects of Δ9-THC and cannabinoid (CB1) receptor gene expression in mice. Behav Brain Res 72:115-125
152. Oz M, Zhang L, Morales M(2002) Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes. Synapse 46:150-156
153. Pan X, Ikeda SR, Lewis DL (1998) SR 141716A acts as an inverse agonist to increase neuronal voltage-dependentCa2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 54:1064-1072
154. Papahatjis DP, Nikas SP, Andreou T, Makriyannis A (2002) Novel 1',1'-chain substituted Δ8-Tetrahydrocannabinols. Bioorg Med Chem Lett 12:3583-3586
155. Pate DW(1999) Anandamide structure-Activity relationships and mechanisms of action on intraocular pressure in the normotensive rabbit model. Doctoral dissertation. Kuopio University Publications, Kuopio
156. Paton GS, Pertwee RG, Davies SN (1998) Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice. Neuropharmacology 37:1123-1130
157. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A (1995) AM630, a competitive cannabinoid receptor antagonist. Life Sci 56:1949-1955
158. Pertwee RG (1988) The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 36:189-261
159. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180
160. Pertwee RG (1999a) Pharmacology of cannabinoid receptor ligands. CurrMed Chem 6:635-664
161. Pertwee RG (1999b) Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci 65:597-605
162. Pertwee RG (2000) Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs 9:1553-1571
163. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611
164. Pertwee RG (2003) Inverse agonism at cannabinoid receptors. In: IJzerman AP (ed) Inverse agonism. Elsevier, Amsterdam, pp 75-86
165. Pertwee RG(2004a)Novel pharmacological targets for cannabinoids. CurrNeuropharmacol 2:9-29
166. Pertwee RG (2004b) The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V (ed) Cannabinoids Kluwer Academic/Plenum Publishers, New York, pp 32-83
167. Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324
168. Pertwee RG, Ross RA(2002) Cannabinoid receptors and their ligands.Prostaglandins Leukot Essent Fatty Acids 66:101-121
169. Pertwee RG, Coutts AA, Griffin G, Fernando SR, McCallion D, Stevenson L (1996a) Presence of cannabinoid CB1 receptors on prejunctional neurones of certain isolated tissue preparations: A brief review. Med Sci Monit 2:840-848
170. Pertwee RG, Fernando SR, Griffin G, Ryan W, Razdan RK, Compton DR, Martin BR (1996b) Agonist-Antagonist characterization of 6'-cyanohex-2'-yne-Δ8- Tetrahydrocannabinol in two isolated tissue preparations. Eur J Pharmacol 315:195-201
171. Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, Saha B, Razdan RK, Martin BR (2000) O-1057, a potentwater-soluble cannabinoid receptor agonistwith antinociceptive properties. Br J Pharmacol 129:1577-1584
172. Pertwee RG, Ross RA, Craib SJ, Thomas A (2002) (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in themouse vas deferens. Eur J Pharmacol 456:99-106
173. Petitet F, Marin L, Doble A (1996) Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A. Neuroreport 7:789-792
174. Petitet F, Jeantaud B, Capet M, Doble A (1997) Interaction of brain cannabinoid receptors with guanine nucleotide binding protein. A radioligand binding study. Biochem Pharmacol 54:1267-1270
175. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC(1998)Complex pharmacology of natural cannabinoids: Evidence for partial agonist activity of Δ9-Tetra Hydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:PL1-PL6
176. Platt B, Drysdale AJ (2004) Search and rescue: Identification of cannabinoid actions relevant for neuronal survival and protection. Curr Neuropharmacol 2:103-114
177. Porter AC, Sauer J-M, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020-1024
178. Portier M, Rinaldi-Carmona M, Pecceu F, Combes T, Poinot-Chazel C, Calandra B, Barth F, Le Fur G, Casellas P (1999) SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther 288:582-589
179. Rhee M-H, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, Breuer A, Mechoulam R (1997) Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylyl cyclase. J Med Chem 40:3228-3233
180. Richardson JD, Kilo S, Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111-119
181. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G(1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244
182. Rinaldi-Carmona M, Calandra B, Shire D, Bouaboula M, Oustric D, Barth F, Casellas P, Ferrara P, Le Fur G (1996a) Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther 278:871-878
183. Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, Brelière J-C, Soubrié P, Le Fur G (1996b) Characterization and distribution of binding sites for [3H]-SR141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci 58:1239-1247
184. Rinaldi-Carmona M, Barth F, Millan J, Derocq J-M, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière J-C, Le Fur G(1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650
185. Ross RA (2003) Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140:790-801
186. Ross RA, Brockie HC, Fernando SR, Saha B, Razdan RK, Pertwee RG (1998) Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Br J Pharmacol 125:1345-1351
187. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG (1999a) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126:665-672
188. Ross RA, Gibson TM, Stevenson LA, Saha B, Crocker P, Razdan RK, Pertwee RG (1999b) Structural determinants of the partial agonist-inverse agonist properties of 6'-Azidohex-2'-yne-Δ8-Tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol 128:735-743
189. Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, Di Marzo V, Pertwee RG (2001) Structure-Activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 132:631-640
190. Rubovitch V, Gafni M, Sarne Y (2002) The cannabinoid agonist DALN positively modulates L-Type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells.Mol Brain Res 101:93-102
191. Ruiu S, Pinna GA, Marchese G, Mussinu J-M, Saba P, Tambaro S, Casti P, Vargiu R, Pani L (2003) Synthesis and characterization of NESS 0327: A novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 306:363-370
192. Savinainen JR, Järvinen T, Laine K, Laitinen JT (2001) Despite substantial degradation, 2-Arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor-dependent G-protein activation in rat cerebellar membranes. Br J Pharmacol 134:664-672
193. Savinainen JR, Saario SM, Niemi R, Järvinen T, Laitinen JT (2003) An optimized approach to study endocannabinoid signaling: Evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 140:1451-1459
194. Schlicker E, Kathmann M(2001)Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22:565-572
195. Schlicker E, Redmer A, Werner A, Kathmann M (2003) Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine. Br J Pharmacol 140:323-328
196. Selley DE, Stark S, Sim LJ, Childers SR(1996)Cannabinoid receptor stimulationof guanosine-5'-O-(3-[35S]thio)triphosphate binding in rat brain membranes. Life Sci 59:659-668
197. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R (1997) Structural requirements for binding of anandamide-Type compounds to the brain cannabinoid receptor. J Med Chem 40:659-667
198. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Caput D, Ferrara P (1995) An amino-Terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 270:3726-3731
199. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessègue B, Bonnin-Cabanne O, Le Fur G, Caput D, Ferrara P (1996)Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307:132-136
200. Showalter VM, Compton DR, Martin BR, Abood ME(1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989-999
201. Sim LJ, Selley DE, Childers SR (1995) In vitro autoradiography of receptor-Activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[γ-[35S]thio]triphosphate binding. Proc Natl Acad Sci USA 92:7242-7246
202. Sim-Selley LJ, Brunk LK, Selley De (2001) Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 414:135-143
203. Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, Makriyannis A, Malan TP (2001) The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology 94:882-887
204. Smart D, Jonsson K-O, Vandevoorde S, Lambert DM, Fowler CJ (2002) 'Entourage' effects of N-Acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br J Pharmacol 136:452-458
205. Song Z-H, Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2.Mol Pharmacol 49:891-896
206. Storr M, Gaffal E, Saur D, Schusdziarra V, Allescher HD (2002) Effect of cannabinoids on neural transmission in rat gastric fundus. Can J Physiol Pharmacol 80:67-76
207. Sugiura T, Kodaka T, Kondo S, Tonegawa T, Nakane S, Kishimoto S, Yamashita A, Waku K (1996) 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun 229:58-64
208. Sugiura T, Kodaka T, Kondo S, Nakane S, Kondo H, Waku K, Ishima Y, Watanabe K, Yamamoto I (1997) Is the cannabinoid CB1 receptor a 2-Arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells. J Biochem (Tokyo) 122:890-895
209. Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K (2000) Evidence that 2-Arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoidCB2receptor: Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275:605-612
210. Suhara Y, Takayama H, Nakane S, Miyashita T, Waku K, Sugiura T (2000) Synthesis and biological activities of 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, and its metabolically stable ether-linked analogues. Chem Pharm Bull (Tokyo) 48:903-907
211. Suhara Y, Nakane S, Arai S, Takayama H, Waku K, Ishima Y, Sugiura T (2001) Synthesis and biological activities of novel structural analogues of 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Bioorg Med Chem Lett 11:1985-1988
212. Tao Q, Abood ME (1998) Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther 285:651-658
213. Thomas A, Ross RA, Saha B, Mahadevan A, Razdan RK, Pertwee R (2004) 6-Azidohex-2-yne-cannabidiol: A potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur J Pharmacol 487:213-221
214. Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M, Matera M, Geppetti P, Bianchi A (2001) Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 21:1104-1109
215. Trendelenburg AU, Cox SL, Schelb V, Klebroff W, Khairallah L, Starke K(2000)Modulation of 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and β-Adrenoceptors in mouse tissues. Br J Pharmacol 130:321-330
216. Ueda N(2002) Endocannabinoid hydrolases. ProstaglandinsOther LipidMediat 68-69:521-534
217. Van Der Stelt M, Di Marzo V (2004) Metabolic fate of endocannabinoids. Curr Neuropharmacol 2:37-48
218. Van Der Stelt M, Veldhuis WB, Maccarrone M, Bär PR, Nicolay K, Veldink GA, Di Marzo V, Vliegenthart JFG (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26:317-346
219. Vásquez C, Navarro-Polanco RA, Huerta M, Trujillo X, Andrade F, Trujillo-Hernández B, Hernández L (2003) Effects of cannabinoids on endogenous K+ and Ca2+ currents in HEK293 cells. Can J Physiol Pharmacol 81:436-442
220. Wager-Miller J, Westenbroek R, Mackie K (2002) Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids 121:83-89
221. Wagner JA, Varga K, Járai Z, Kunos G(1999)Mesenteric vasodilationmediatedbyendothelial anandamide receptors. Hypertension 33:429-434
222. Walker JM, Krey JF, Chu CJ, Huang SM (2002) Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 121:159-172
223. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398-1405
224. White R, Hiley CR (1998) The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br J Pharmacol 125:689-696
225. Wiley JL, Martin BR(2002)Cannabinoid pharmacology:implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 121:57-63
226. Wiley JL, Martin BR (2003) Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol 471:185-193
227. Wiley JL, Beletskaya ID, Ng EW, Dai Z, Crocker PJ, Mahadevan A, Razdan RK, Martin BR (2002) Resorcinol derivatives: A novel template for the development of cannabinoid CB1/CB2 and CB2-selective agonists. J Pharmacol Exp Ther 301:679-689
228. Wrobleski ST, Chen P, Hynes J, Lin S, Norris DJ, Pandit CR, Spergel S, Wu H, Tokarski JS, Chen X, Gillooly KM, Kiener PA, McIntyre KW, Patil-Koota V, Shuste rDJ, Turk LA, Yang G, Leftheris K (2003) Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J Med Chem 46:2110-2116
229. Yao L, Fan P, Jiang Z, Mailliard WS, Gordon AS, Diamond I (2003) Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi-βγdimers. Proc Natl Acad Sci USA 100:14379-14384
230. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sfrgård M, Di Marzo V, Julius D, Högestätt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457
231. Zygmunt PM, Andersson DA, Högestätt ED(2002)Δ9-Tetra Hydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptorindependent mechanism. J Neurosci 22:4720-4727